PubMed:17600377 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCoin-sentences

{"project":"LitCoin-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":141},"obj":"Sentence"},{"id":"T2","span":{"begin":142,"end":333},"obj":"Sentence"},{"id":"T3","span":{"begin":334,"end":509},"obj":"Sentence"},{"id":"T4","span":{"begin":510,"end":731},"obj":"Sentence"},{"id":"T5","span":{"begin":732,"end":830},"obj":"Sentence"},{"id":"T6","span":{"begin":831,"end":944},"obj":"Sentence"},{"id":"T7","span":{"begin":945,"end":1109},"obj":"Sentence"},{"id":"T8","span":{"begin":1110,"end":1370},"obj":"Sentence"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

LitCoin-entities-OrganismTaxon-PD

{"project":"LitCoin-entities-OrganismTaxon-PD","denotations":[{"id":"T1","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":504,"end":508},"obj":"OrganismTaxon"},{"id":"T7","span":{"begin":581,"end":584},"obj":"OrganismTaxon"},{"id":"T9","span":{"begin":672,"end":683},"obj":"OrganismTaxon"},{"id":"T10","span":{"begin":726,"end":730},"obj":"OrganismTaxon"}],"attributes":[{"id":"A7","pred":"db_id","subj":"T7","obj":"NCBItxid:10116"},{"id":"A8","pred":"db_id","subj":"T7","obj":"NCBItxid:10114"},{"id":"A4","pred":"db_id","subj":"T4","obj":"NCBItxid:10118"},{"id":"A5","pred":"db_id","subj":"T4","obj":"NCBItxid:10116"},{"id":"A6","pred":"db_id","subj":"T4","obj":"NCBItxid:10114"},{"id":"A9","pred":"db_id","subj":"T9","obj":"NCBItxid:72046"},{"id":"A10","pred":"db_id","subj":"T10","obj":"NCBItxid:10118"},{"id":"A11","pred":"db_id","subj":"T10","obj":"NCBItxid:10116"},{"id":"A12","pred":"db_id","subj":"T10","obj":"NCBItxid:10114"},{"id":"A1","pred":"db_id","subj":"T1","obj":"NCBItxid:10118"},{"id":"A2","pred":"db_id","subj":"T1","obj":"NCBItxid:10116"},{"id":"A3","pred":"db_id","subj":"T1","obj":"NCBItxid:10114"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

LitCoin-entities

LitCoin_Mondo

{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":1309,"end":1317},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0001627"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0004975"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0004466"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

LitCoin-GeneOrGeneProduct-v2

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T1","span":{"begin":2,"end":7},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":155,"end":160},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":328,"end":332},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":477,"end":481},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":645,"end":649},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":699,"end":703},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":906,"end":910},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":926,"end":935},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":1014,"end":1018},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":1029,"end":1036},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

LitCoin-GeneOrGeneProduct-v0

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T1","span":{"begin":2,"end":7},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":40,"end":50},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":155,"end":160},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":328,"end":332},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":477,"end":481},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":544,"end":553},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":616,"end":620},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":628,"end":634},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":645,"end":649},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":699,"end":703},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":824,"end":829},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":831,"end":836},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":906,"end":910},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":926,"end":935},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":1014,"end":1018},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":1029,"end":1036},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":1098,"end":1108},"obj":"GeneOrGeneProduct"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

LitCoin-Disease-MeSH

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T1","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":554,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":650,"end":655},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1019,"end":1024},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1318,"end":1323},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1340,"end":1360},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A2","pred":"originalLabel","subj":"T2","obj":"D003704"},{"id":"A1","pred":"originalLabel","subj":"T1","obj":"DISEASE"},{"id":"A6","pred":"originalLabel","subj":"T6","obj":"D003643"},{"id":"A8","pred":"originalLabel","subj":"T8","obj":"D003643"},{"id":"A3","pred":"originalLabel","subj":"T3","obj":"D060825"},{"id":"A4","pred":"originalLabel","subj":"T4","obj":"DISEASE"},{"id":"A7","pred":"originalLabel","subj":"T7","obj":"D000544"},{"id":"A9","pred":"originalLabel","subj":"T9","obj":"D060825"},{"id":"A5","pred":"originalLabel","subj":"T5","obj":"D003643"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

LitCoin-GeneOrGeneProduct-v3

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T1","span":{"begin":926,"end":935},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

LitCoin_Mondo_095

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":469,"end":476},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":691,"end":698},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":898,"end":905},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A5","pred":"mondo_id","subj":"T5","obj":"0004975"},{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0001627"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0019065"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0019065"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0019065"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

LitCoin-MeSH-Disease-2

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T1","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":554,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":650,"end":655},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1019,"end":1024},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1318,"end":1323},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1340,"end":1360},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"DISEASE"},{"id":"A2","pred":"ID:","subj":"T2","obj":"D003704"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D060825"},{"id":"A4","pred":"ID:","subj":"T4","obj":"DISEASE"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D000544"},{"id":"A6","pred":"ID:","subj":"T6","obj":"D003643"},{"id":"A8","pred":"ID:","subj":"T8","obj":"D003643"},{"id":"A9","pred":"ID:","subj":"T9","obj":"D060825"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D003643"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

LitCoin_CellLine

{"project":"LitCoin_CellLine","denotations":[{"id":"T1","span":{"begin":816,"end":823},"obj":"CellLine"}],"attributes":[{"id":"A1","pred":"cellosaurus_accession_id","subj":"T1","obj":"CVCL_0019"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

LitCoin-MONDO_bioort2019

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T1","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":554,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1340,"end":1360},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"#label","subj":"T1","obj":"DISEASE"},{"id":"A5","pred":"#label","subj":"T5","obj":"D000544"},{"id":"A3","pred":"#label","subj":"T3","obj":"D060825"},{"id":"A2","pred":"#label","subj":"T2","obj":"D003704"},{"id":"A6","pred":"#label","subj":"T6","obj":"D060825"},{"id":"A4","pred":"#label","subj":"T4","obj":"DISEASE"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

LitCoin-Chemical-MeSH-CHEBI

LitCoin-NCBITaxon-2

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":504,"end":508},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":581,"end":584},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":726,"end":730},"obj":"OrganismTaxon"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

LitCoin-training-merged

PubmedHPO

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":415,"end":432},"obj":"HP_0001268"},{"id":"T2","span":{"begin":469,"end":476},"obj":"HP_0011034"},{"id":"T3","span":{"begin":554,"end":572},"obj":"HP_0100543"},{"id":"T4","span":{"begin":691,"end":698},"obj":"HP_0011034"},{"id":"T5","span":{"begin":898,"end":905},"obj":"HP_0011034"},{"id":"T6","span":{"begin":1252,"end":1271},"obj":"HP_0002511"},{"id":"T7","span":{"begin":1328,"end":1360},"obj":"HP_0001268"},{"id":"T8","span":{"begin":1340,"end":1360},"obj":"HP_0001268"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-deepseek-nr-ng

{"project":"biored-valid-deepseek-nr-ng","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":260,"end":266},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T4","span":{"begin":380,"end":400},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":816,"end":829},"obj":"CellLine"},{"id":"T8","span":{"begin":858,"end":878},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid

{"project":"biored-valid","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":260,"end":280},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":306,"end":312},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":380,"end":400},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T11","span":{"begin":469,"end":495},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":504,"end":508},"obj":"OrganismTaxon"},{"id":"T13","span":{"begin":510,"end":530},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":554,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T15","span":{"begin":581,"end":584},"obj":"OrganismTaxon"},{"id":"T16","span":{"begin":691,"end":717},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":726,"end":730},"obj":"OrganismTaxon"},{"id":"T18","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":816,"end":823},"obj":"CellLine"},{"id":"T20","span":{"begin":858,"end":878},"obj":"ChemicalEntity"},{"id":"T21","span":{"begin":898,"end":924},"obj":"ChemicalEntity"},{"id":"T22","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T23","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T24","span":{"begin":959,"end":979},"obj":"ChemicalEntity"},{"id":"T25","span":{"begin":1037,"end":1060},"obj":"ChemicalEntity"},{"id":"T26","span":{"begin":1062,"end":1074},"obj":"ChemicalEntity"},{"id":"T27","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":1186,"end":1206},"obj":"ChemicalEntity"},{"id":"T29","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T30","span":{"begin":1309,"end":1323},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T31","span":{"begin":1340,"end":1369},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-deepseek-nr-g

{"project":"biored-valid-deepseek-nr-g","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":260,"end":280},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T4","span":{"begin":380,"end":400},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":469,"end":489},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":489,"end":495},"obj":"SequenceVariant"},{"id":"T8","span":{"begin":510,"end":530},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-deepseek-r-ng

{"project":"biored-valid-deepseek-r-ng","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":125,"end":140},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":260,"end":266},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":276,"end":279},"obj":"OrganismTaxon"},{"id":"T6","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T10","span":{"begin":469,"end":495},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":635,"end":655},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T12","span":{"begin":816,"end":829},"obj":"CellLine"},{"id":"T13","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T15","span":{"begin":1037,"end":1060},"obj":"ChemicalEntity"},{"id":"T16","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-deepseek-r-g

{"project":"biored-valid-deepseek-r-g","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":260,"end":266},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T9","span":{"begin":469,"end":495},"obj":"SequenceVariant"},{"id":"T10","span":{"begin":816,"end":829},"obj":"CellLine"},{"id":"T11","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":1037,"end":1060},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T17","span":{"begin":1309,"end":1323},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T18","span":{"begin":1328,"end":1369},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-gemini-nr-ng

{"project":"biored-valid-gemini-nr-ng","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":260,"end":280},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":380,"end":400},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T10","span":{"begin":469,"end":495},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":510,"end":530},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":554,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":635,"end":655},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":691,"end":717},"obj":"ChemicalEntity"},{"id":"T15","span":{"begin":726,"end":730},"obj":"OrganismTaxon"},{"id":"T16","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":816,"end":823},"obj":"CellLine"},{"id":"T18","span":{"begin":898,"end":924},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T20","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T21","span":{"begin":959,"end":979},"obj":"ChemicalEntity"},{"id":"T22","span":{"begin":1004,"end":1024},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T23","span":{"begin":1037,"end":1060},"obj":"ChemicalEntity"},{"id":"T24","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":1186,"end":1206},"obj":"ChemicalEntity"},{"id":"T27","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T28","span":{"begin":1309,"end":1323},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T29","span":{"begin":1328,"end":1369},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-gemini-r-ng

{"project":"biored-valid-gemini-r-ng","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":80,"end":103},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":199,"end":217},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":222,"end":237},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":260,"end":280},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T12","span":{"begin":469,"end":495},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":504,"end":508},"obj":"OrganismTaxon"},{"id":"T14","span":{"begin":510,"end":530},"obj":"ChemicalEntity"},{"id":"T15","span":{"begin":554,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T16","span":{"begin":635,"end":655},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T17","span":{"begin":691,"end":717},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":753,"end":776},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T19","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T20","span":{"begin":816,"end":829},"obj":"CellLine"},{"id":"T21","span":{"begin":858,"end":878},"obj":"ChemicalEntity"},{"id":"T22","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T23","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T24","span":{"begin":1037,"end":1060},"obj":"ChemicalEntity"},{"id":"T25","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T28","span":{"begin":1309,"end":1323},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T29","span":{"begin":1340,"end":1369},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-gemini-r-g

{"project":"biored-valid-gemini-r-g","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":260,"end":280},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T9","span":{"begin":469,"end":495},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":504,"end":508},"obj":"OrganismTaxon"},{"id":"T11","span":{"begin":510,"end":530},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":554,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":691,"end":717},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T15","span":{"begin":816,"end":823},"obj":"CellLine"},{"id":"T16","span":{"begin":858,"end":878},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T18","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T22","span":{"begin":1309,"end":1323},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T23","span":{"begin":1340,"end":1369},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-gpt-nr-ng

{"project":"biored-valid-gpt-nr-ng","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":260,"end":280},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":380,"end":400},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T10","span":{"begin":469,"end":495},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":510,"end":530},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":581,"end":584},"obj":"OrganismTaxon"},{"id":"T13","span":{"begin":635,"end":655},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":691,"end":717},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":726,"end":730},"obj":"OrganismTaxon"},{"id":"T16","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":816,"end":823},"obj":"CellLine"},{"id":"T18","span":{"begin":858,"end":878},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":898,"end":924},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T21","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T22","span":{"begin":959,"end":979},"obj":"ChemicalEntity"},{"id":"T23","span":{"begin":1004,"end":1024},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T24","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":1186,"end":1206},"obj":"ChemicalEntity"},{"id":"T27","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T28","span":{"begin":1309,"end":1323},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-gpt-r-g

{"project":"biored-valid-gpt-r-g","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":260,"end":280},"obj":"ChemicalEntity"},{"id":"T4","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":380,"end":400},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T8","span":{"begin":469,"end":495},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":510,"end":530},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":581,"end":584},"obj":"OrganismTaxon"},{"id":"T11","span":{"begin":691,"end":717},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":726,"end":730},"obj":"OrganismTaxon"},{"id":"T13","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":816,"end":823},"obj":"CellLine"},{"id":"T15","span":{"begin":858,"end":878},"obj":"ChemicalEntity"},{"id":"T16","span":{"begin":898,"end":924},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T18","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":959,"end":979},"obj":"ChemicalEntity"},{"id":"T20","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":1186,"end":1206},"obj":"ChemicalEntity"},{"id":"T23","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-gpt-nr-g

{"project":"biored-valid-gpt-nr-g","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":260,"end":280},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":380,"end":400},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T10","span":{"begin":469,"end":495},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":510,"end":530},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":554,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":581,"end":584},"obj":"OrganismTaxon"},{"id":"T14","span":{"begin":691,"end":717},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":726,"end":730},"obj":"OrganismTaxon"},{"id":"T16","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":816,"end":823},"obj":"CellLine"},{"id":"T18","span":{"begin":858,"end":878},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":898,"end":924},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T21","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T22","span":{"begin":959,"end":979},"obj":"ChemicalEntity"},{"id":"T23","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":1186,"end":1206},"obj":"ChemicalEntity"},{"id":"T26","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-gpt-r-ng

{"project":"biored-valid-gpt-r-ng","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":260,"end":280},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":306,"end":312},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":380,"end":400},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T11","span":{"begin":469,"end":495},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":504,"end":508},"obj":"OrganismTaxon"},{"id":"T13","span":{"begin":510,"end":530},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":554,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T15","span":{"begin":581,"end":584},"obj":"OrganismTaxon"},{"id":"T16","span":{"begin":635,"end":655},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T17","span":{"begin":691,"end":717},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":726,"end":730},"obj":"OrganismTaxon"},{"id":"T19","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T20","span":{"begin":816,"end":823},"obj":"CellLine"},{"id":"T21","span":{"begin":858,"end":878},"obj":"ChemicalEntity"},{"id":"T22","span":{"begin":898,"end":924},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T24","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T25","span":{"begin":959,"end":979},"obj":"ChemicalEntity"},{"id":"T26","span":{"begin":1004,"end":1024},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T27","span":{"begin":1037,"end":1060},"obj":"ChemicalEntity"},{"id":"T28","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":1186,"end":1206},"obj":"ChemicalEntity"},{"id":"T31","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T32","span":{"begin":1309,"end":1323},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T33","span":{"begin":1328,"end":1369},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-gemini-nr-g

{"project":"biored-valid-gemini-nr-g","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":260,"end":280},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T9","span":{"begin":469,"end":495},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":504,"end":507},"obj":"OrganismTaxon"},{"id":"T11","span":{"begin":510,"end":530},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":554,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":635,"end":655},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":691,"end":717},"obj":"ChemicalEntity"},{"id":"T15","span":{"begin":726,"end":730},"obj":"OrganismTaxon"},{"id":"T16","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":816,"end":823},"obj":"CellLine"},{"id":"T18","span":{"begin":858,"end":878},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":898,"end":924},"obj":"ChemicalEntity"},{"id":"T20","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T21","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T22","span":{"begin":959,"end":979},"obj":"ChemicalEntity"},{"id":"T23","span":{"begin":1004,"end":1024},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T24","span":{"begin":1037,"end":1060},"obj":"ChemicalEntity"},{"id":"T25","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T28","span":{"begin":1309,"end":1323},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T29","span":{"begin":1340,"end":1369},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-gpt-r-m

{"project":"biored-valid-gpt-r-m","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":260,"end":280},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":380,"end":400},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T10","span":{"begin":469,"end":495},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":510,"end":530},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":554,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":581,"end":584},"obj":"OrganismTaxon"},{"id":"T14","span":{"begin":691,"end":717},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":726,"end":730},"obj":"OrganismTaxon"},{"id":"T16","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":816,"end":829},"obj":"CellLine"},{"id":"T18","span":{"begin":858,"end":878},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":898,"end":924},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T21","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T22","span":{"begin":959,"end":979},"obj":"ChemicalEntity"},{"id":"T23","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":1186,"end":1206},"obj":"ChemicalEntity"},{"id":"T26","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T27","span":{"begin":1328,"end":1369},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-gemini-r-m

{"project":"biored-valid-gemini-r-m","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":260,"end":280},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T9","span":{"begin":469,"end":495},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":504,"end":507},"obj":"OrganismTaxon"},{"id":"T11","span":{"begin":510,"end":530},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":554,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":635,"end":655},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":691,"end":717},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":726,"end":730},"obj":"OrganismTaxon"},{"id":"T16","span":{"begin":780,"end":800},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":816,"end":829},"obj":"CellLine"},{"id":"T18","span":{"begin":858,"end":878},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":898,"end":924},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T21","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T22","span":{"begin":1004,"end":1024},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T23","span":{"begin":1037,"end":1060},"obj":"ChemicalEntity"},{"id":"T24","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":1186,"end":1206},"obj":"ChemicalEntity"},{"id":"T27","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T28","span":{"begin":1309,"end":1323},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T29","span":{"begin":1340,"end":1369},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}

biored-valid-deepseek-r-m

{"project":"biored-valid-deepseek-r-m","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":51,"end":69},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":125,"end":133},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":260,"end":266},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":317,"end":332},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":415,"end":432},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":436,"end":447},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":457,"end":461},"obj":"OrganismTaxon"},{"id":"T9","span":{"begin":469,"end":495},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":581,"end":584},"obj":"OrganismTaxon"},{"id":"T11","span":{"begin":816,"end":829},"obj":"CellLine"},{"id":"T12","span":{"begin":926,"end":935},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":939,"end":943},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":1062,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":1088,"end":1097},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":1252,"end":1271},"obj":"DiseaseOrPhenotypicFeature"}],"text":"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.\nTo develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function."}